Holly Hacker | KFF Health News
The recall affects the only medical option for many patients with end-stage heart failure who do not qualify for a transplant.
The FDA said nothing about the payments from the North Chicago company when the panel met to assess new technology, a “breakthrough device” for which the agency “may be willing to accept greater uncertainty” when considering risks and benefits.